Analysis showed that 25–30% of these tumor-infiltrating neutrophils expressed the CD71 protein, which was notably absent from most of the other neutrophils outside the brain tumor. The team ...

The results of Phase III trials of the CD20-targeted human monoclonal antibody (mAb) ofatumumab in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) dampen hopes on the potential of the drug ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

The results from the first human trial of ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of rheumatoid arthritis (RA) have recently been presented. Genovese et al.